Long-Term Survival in Unfavourable-Risk mRCC Patients After Intratumoral Administration of a Cell-Based Allogeneic Vaccine
Journal for ImmunoTherapy of Cancer - United Kingdom
doi 10.1186/2051-1426-3-s2-p438
Full Text
Open PDFAbstract
Available in full text
Date
November 4, 2015
Authors
Publisher
BMJ